UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549





Form
10-K/A 2


(Mark
One)


√  ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934


For the
fiscal year ended  December 31, 2007





TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934


For the
transition period from _______ to_________





Commission
file number 0-12968





INMEDICA
DEVELOPMENT CORPORATION


(Name of
small business issuer in its charter)





Utah
            87-0397815(State
      of Incorporation)
            (I.R.S.
      Employer Identification No.)





825 North
300 West, Suite N132


Salt Lake
City, Utah 84103


(801)
521-9300





Securities
Registered Pursuant to Section 12(g) of the Act:





Name of
Each Exchange





Title of Each Class
            on which RegisteredCommon
      Stock, $.001 par value
            None





Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities
Act.       [  ]  Yes   [√] No





Indicate
by check mark if the registrant is required to file reports pursuant to Section
13 or Section 15(d) of the Act  [√
]  Yes   [ ] No





Indicate
by check mark whether the issuer (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days.         √
Yes            No





Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and no disclosure will be contained, to
the best of registrant’s knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K.    √


1


Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company.   See the definitions of “large accelerated filer,”
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act.





Large
      accelerated filer [  ]
            Accelerated
      filer  [  ]Non-accelerated
      filer [  ]
            Smaller
      reporting company [√](do
      not check if a smaller reporting company)





Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange
Act).     Yes    No  √





State the
aggregate market value of the voting and non-voting common equity held by
non-affiliates:  $186,908 based on 8,693,402 non affiliate shares
outstanding at $.0215 per share, which is the average bid and asked price of the
common shares as of the last business day of the registrant’s most recently
completed second fiscal quarter.





Indicate
the number of shares outstanding of each of the issuer’s classes of common
stock, as of the latest practicable date: 18,629,493 shares of common stock,
$.001 par value as of August 31, 2008





DOCUMENTS
INCORPORATED BY REFERENCE





List
hereunder the following documents if incorporated by reference and the Part of
the form 10-K (e.g., Part I, Part II, etc.) into which the document is
incorporated: (1) any annual report to security holders; (2) any proxy or
information statement; and (3) any prospectus filed pursuant to Rule 424(b) or
(c) of the Securities Act of 1933 (“Securities Act”). The listed documents
should be clearly described for identification purposes (e.g., annual report to
security holders for fiscal year ended December 24,
1980).         None








2


The
Registrant hereby amends Item 9A(T) – Controls and Procedures and Item 15
Exhibits of its Form 10K report for the year ended December 31, 2007, which
Items are amended and restated in their entirety below, together with the
attachment of Exhibits.





ITEM
9A(T) – CONTROLS AND PROCEDURES





Evaluation of Disclosure Controls and
Procedures.





InMedica
Management is responsible for establishing and maintaining adequate
disclosure control over financial reporting, as defined in the Securities
Exchange Act of 1934 Rule 13a-15(e).  InMedica’s Board of Directors
provides oversight to its financial reporting process.





InMedica
evaluated the effectiveness of the design and operation of its disclosure
controls and procedures during 2007.    Based on that
evaluation, InMedica’s Principal Executive Officer and Principal Financial
Officer initially concluded that, as of December 31, 2007, its disclosure
controls and procedures are effective.   However they
subsequently amended the conclusion and found that the Company’s disclosure
controls as of December 31, 2007 were ineffective due to the Company’s
inadvertent failure to provide its report on internal control over financial
reporting as a part of Form 10K for the year ended December 31,
2007.   The Company has since filed its report on internal
control for the year ended December 31, 2007 (See Exhibit 99 of Form 10K/A1
filed August 12, 2008) and has also revised its disclosure controls to assure
that the required report on internal controls is reported in its
filings.





Management’s
Report on Internal Control Over Financial Reporting.





Pursuant
to Section 404 of the Sarbanes-Oxley Act of 2002, the Company has included,
as part of this Form 10-K, a report of management's assessment of the
effectiveness of its internal controls as of December 31,
2007.  The independent registered public accounting firm of InMedica
has not audited the effectiveness of the Company's internal control over
financial reporting due to an exemption from such requirement for 2007 annual
reports of small business issuers. Management's report appears in
Form 10-K/A1 as Exhibit 99 and is incorporated herein by
reference.





Changes
in Internal Control Over Financial Reporting.





There
have been no changes in InMedica’s internal control over financial reporting
that materially affected, or were reasonably likely to materially affect, the
Company’s internal control over financial reporting during the fourth quarter of
the fiscal year ended December 31, 2007, and there were no material
weaknesses.





3


Item
15. Exhibits





(1)  Financial
Statements




PageIndependent
      Registered Public Accountants’ Report (Robison, Hill &
      Company)
            F-1Consolidated
      Balance Sheet as of December 31, 2007 and 2006
            F-3Consolidated
      Statements of Operations for theYears
      Ended December 31, 2007 and 2006
            F-4Consolidated
      Statements of Stockholders’ Equity for theYears
      Ended December 31, 2007 and 2006
            F-5Consolidated
      Statements of Cash Flows for theYears
      Ended December 31, 2007 and 2006
            F-6Notes
      to Consolidated Financial Statements
            F-7





(3)  Exhibits
required by Item 601:




S-K
      No.
            Description(31.1)
            Sarbanes-Oxley
      Section 302 Certification – Ralph Henson(31.1)
            Sarbanes-
      Oxley Section 302 Certification- Richard Bruggeman(32.1)
            Sarbanes-Oxley
      Section 906 Certification(99)
            Management’s
      Report On Internal Control Over Financial Reporting – incorporated by
      reference to Exhibit 99 of the Form 10K/A1 filed August 12,
      2008.







4







SIGNATURES





Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, the Registrant caused this Form 10K/A 2 report to be signed on its
behalf by the undersigned, thereunto duly authorized.




INMEDICA
DEVELOPMENT CORPORATION





Date:   September 26
      ,  2008
            By
            /s/
      Ralph HensonRALPH
      HENSON,President
      & Chief Executive OfficerBy
            /s/
      Richard BruggemanRICHARD
      BRUGGEMANChief
      Financial Officer








In
accordance with the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the Registrant and in the capacities
and on the dates indicated.








/s/
      Larry E. Clark
            DATE:   September 26 ,
      2008LARRY
      E. CLARK, Director/s/
      Richard Bruggeman
            DATE:   September 26 ,  2008RICHARD
      BRUGGEMAN, Director/s/
      Ralph Henson
            DATE:   September 22 ,
      2008RALPH
      HENSON, Director










5








EXHIBIT
INDEX – INMEDICA DEVELOPMENT CORPORATION


FORM
10-K/A 2   – FOR THE YEAR ENDED DECEMBER 31, 2007





Exhibit
      31.1
            CERTIFICATION
      PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 – Ralph
      HensonExhibit
      31.2
            CERTIFICATION
      PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 – Richard
      BruggemanExhibit
      32.1
            CERTIFICATE
      PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF
      THE SARBANES-OXLEY ACT OF 2002